Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone512-519-0400
Debt
Current Ratio5.28
Quick Ratio5.23
Price-To-Earnings
Sales & Book Value
Annual Sales$3.12 million
Price / Sales16.19
Price / Cash FlowN/A
Price / Book11.17
Profitability
Net Income$-10,490,000.00
Net Margins-392.83%
Return on Assets-108.24%
Miscellaneous
Employees40
OptionableOptionable
Vermillion (NASDAQ:VRML) Frequently Asked Questions
What is Vermillion's stock symbol?
Vermillion trades on the NASDAQ under the ticker symbol "VRML."
How were Vermillion's earnings last quarter?
Vermillion, Inc. (NASDAQ:VRML) announced its quarterly earnings data on Thursday, November, 8th. The company reported ($0.04) EPS for the quarter, meeting analysts' consensus estimates of ($0.04). The company earned $0.77 million during the quarter. Vermillion had a negative net margin of 392.83% and a negative return on equity of 174.33%. View Vermillion's Earnings History.
When is Vermillion's next earnings date?
What price target have analysts set for VRML?
1 equities research analysts have issued twelve-month price targets for Vermillion's shares. Their forecasts range from $2.25 to $2.25. On average, they expect Vermillion's stock price to reach $2.25 in the next year. This suggests a possible upside of 235.7% from the stock's current price. View Analyst Price Targets for Vermillion.
What is the consensus analysts' recommendation for Vermillion?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vermillion in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vermillion.
Has Vermillion been receiving favorable news coverage?
News coverage about VRML stock has been trending negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vermillion earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.
Are investors shorting Vermillion?
Vermillion saw a decrease in short interest during the month of December. As of December 14th, there was short interest totalling 455,365 shares, a decrease of 33.6% from the November 30th total of 686,120 shares. Based on an average daily trading volume, of 86,744 shares, the days-to-cover ratio is currently 5.2 days. Approximately 1.1% of the company's stock are short sold. View Vermillion's Current Options Chain.
Who are some of Vermillion's key competitors?
Some companies that are related to Vermillion include Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Riot Blockchain (RIOT), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), GeneNews (GNWSF), Arca Biopharma (ABIO), Fluoropharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ) and Palatin Technologies (PTN).
Who are Vermillion's key executives?
Vermillion's management team includes the folowing people:
- Ms. Valerie Barber Palmieri, CEO, Pres & Director (Age 57)
- Mr. Robert Harry Beechey CPA, Chief Financial Officer (Age 55)
- Mr. Chris Goulart, Sr. VP of Commercial Operations
- Mr. Patrick Carpenter, Gen. Mang. of ASPiRA LABS
How do I buy shares of Vermillion?
Shares of VRML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vermillion's stock price today?
One share of VRML stock can currently be purchased for approximately $0.6703.
How big of a company is Vermillion?
Vermillion has a market capitalization of $42.21 million and generates $3.12 million in revenue each year. Vermillion employs 40 workers across the globe.
What is Vermillion's official website?
How can I contact Vermillion?
Vermillion's mailing address is 12117 BEE CAVES ROAD BUILDING THREE SUITE 100, AUSTIN TX, 78738. The company can be reached via phone at 512-519-0400 or via email at [email protected]
MarketBeat Community Rating for Vermillion (NASDAQ VRML)
MarketBeat's community ratings are surveys of what our community members think about Vermillion and other stocks. Vote "Outperform" if you believe VRML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRML will underperform the S&P 500 over the long term. You may vote once every thirty days.
